Evaluation of an implant that delivers leuprolide for 1 year for the palliative treatment of prostate cancer

Author： Fowler J.E. Flanagan M. Gleason D.M. Klimberg I.W. Gottesman J.E. Sharifi R.

Publisher： Elsevier

ISSN： 0090-4295

Source： Urology, Vol.55, Iss.5, 2000-05, pp. : 639-642

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Patient-reported experience with the Viadur 12-month leuprolide implant for prostate cancer

By Fowler J.E. the Viadur Study Group

Urology, Vol. 58, Iss. 3, 2001-09 ,pp. : 430-434

Elsevier

Access to resources Recommend Favorite

Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancer

By Sharifi R. Knoll L.D. Smith J. Kramolowsky E.

Urology, Vol. 51, Iss. 2, 1998-02 ,pp. : 271-276

Elsevier

Access to resources Recommend Favorite

Intraoperative treatment planning for radioactive seed implant therapy for prostate cancer

By Kaplan I.D. Holupka E.J. Meskell P. Soon S.J. Saltzman B. Church P. Kearney G.P.

Urology, Vol. 56, Iss. 3, 2000-09 ,pp. : 492-495

Elsevier

Access to resources Recommend Favorite

An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer

By Sartor O. Dineen M.K. Perez-Marreno R. Chu F.M. Carron G.J. Tyler R.C.

Urology, Vol. 62, Iss. 2, 2003-08 ,pp. : 319-323

Elsevier

Access to resources Recommend Favorite

Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study

By Higano C.S. Ellis W. Russell K. Lange P.H.

Urology, Vol. 48, Iss. 5, 1996-11 ,pp. : 800-804

Elsevier

Access to resources Recommend Favorite